Newton Taps ABB Labs to Rapidly Scale Distribution of Neurolens and Sequel Technologies Across North America

New updates have been reported about Newton.

Newton, the eye care technology company formerly known as Neurolens, has entered a strategic lab partnership with ABB Labs that materially expands its distribution, manufacturing redundancy, and service footprint across the U.S. and North America. By integrating its Neurolens and Sequel lens portfolios into ABB’s large independent laboratory network, Newton will make its Contoured Prism and Convergence Boost technologies available to thousands of additional independent optometry practices, significantly extending market reach at a time when Sequel lenses have just become eligible under VSP coverage and thus accessible to millions more insured patients. For Newton, this agreement effectively augments its existing lab network with ABB’s operational scale, quality controls, and logistics capabilities, helping improve product availability and service levels for its growing practitioner base, while reducing friction for practices that prefer to source through a single, established lab partner.

CEO Davis Corley framed the partnership as a “transformative moment” for Newton’s ability to serve independent optometry, signaling a strategic emphasis on channel expansion and execution rather than incremental product launches. ABB Labs, which reports 92% customer satisfaction and a 98% on-spec order rate in an independent study, is expected to support Newton’s growth by providing reliable turnaround and national coverage, helping practices more easily adopt Neurolens for headache, neck pain, motion sickness, and digital-eye-strain relief, and Sequel lenses for on- and off-screen visual comfort. The companies are also using the launch to drive rapid onboarding: new ABB customers that become new Newton customers can access a time-limited incentive designed to lower adoption barriers. For executives and investors, the deal positions Newton to accelerate unit volume through an entrenched independent-eye-care channel, deepen penetration as VSP coverage ramps, and reinforce its positioning as a premium, technology-driven lens provider focused on measurable patient outcomes rather than commodity vision correction.